PETALING JAYA: Duopharma Biotech Bhd
will remain proactively focused on enhancing operational efficiencies, optimising cost management strategies, and disciplined execution of its strategic initiatives.
In a filing with Bursa Malaysia, the pharmaceutical company said the group aims to deliver a satisfactory performance for the financial year ending Dec 31, 2026, barring unforeseen circumstances.
For its fourth quarter ended Dec 31, 2025 rose to RM19.05mil from RM15.08mil in the previous corresponding period, while revenue in the fourth quarter grew to RM224.69mil from RM193.67mil a year earlier.
For the financial year ended Dec 31, 2025 (FY2025), the company recorded revenue of RM931.69mil, up 14.5% from RM813.70mil in FY2024.
“Profit before tax (PBT) and profit after tax in FY2025 respectively increased 43.6% and 39.6% year-on-year.”
Duopharma said the sustained double-digit growth was primarily driven by resilient demand from both the public and private sectors across all business segments, complemented by a one- off surge in insulin supply in the first half of the year following supply normalisation.
“PBT growth was mainly attributable to the higher revenue base, coupled with continued favourable Active Pharmaceutical Ingredient (API) costs, positive foreign exchange movements and improved operational efficiency, which collectively enhanced profitability.”
The company declared a second interim dividend of 3.05 sen per share (2024: 2.0 sen) equivalent to RM 29.34mil (2024: RM19.24mil).“This brings the total dividend for FY2025 to 4.55 sen per share (2024: 3.0 sen), amounting to approximately RM43.77mil, an increase of 51.7% from FY2024,” it said.
